Kun for helsepersonell
Menu
Close
Menu
Close
Normal adult renal function
Adult renal impairment
Tab Number 3
ZAVICEFTA (ceftazidime–avibactam) has consistent dosing across indications, with no dosage adjustments required in the elderly, adult patients with mild renal impairment (estimated CrCl ≥ 51 to ≤80 mL/min) and those with hepatic impairment1
Recommended dose for adult patients with estimated CrCl ≥51 mL/min1*
![]() |
Dosage adjustment is required for patients with renal impairment (estimated CrCl ≤50 mL/min)1
Recommended dose adjustments in adult patients with estimated CrCl ≤50 mL/min:1
![]() |
From the Department Of Medical and Surgical Science, Alma Mater Studiorum, University of Bologna, Italy as he discusses PK/PD attributes of ZAVICEFTA in patients.
Learn more about ZAVICEFTA’s safety and tolerability in adult and paediatric patients.
Pfizer AS, Org.nr 915 213 596
Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo
Tlf.: +47 67 52 61 00
PP-BCP-NOR-0001 juni 2023
Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.
Dette nettstedet er kun for helsepersonell.
Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.
Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.